If you're a stockholder of Myriad Genetics (NASDAQ:MYGN) you're probably feeling a little queasy right now and wondering why the stock is now falling fast after initially reacting positively to Thursday's Supreme Court Decision. After all, the ruling in Association for Molecular Pathology v. Myriad Genetics Inc. was exactly what most observers and analysts expected. A reasonable investor would think that this outcome would already be factored into the stock price, but most analysts were sticking to their outperform ratings on the stock after the decision, only to reverse course and downgrade the stock after it fell in Thursday and Friday's sessions.
So what went wrong? Where was the disconnect between what the Street expected and what actually...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|